Volume : 09, Issue : 03, March – 2022

Title:

35.AN OVERVIEW PHARMACIST’S ROLE IN PREVENTING MEASURES TOWARD ANTIBIOTIC RESISTANCE
‏‬

Authors :

Ahmed Othman Almailabi, Alhumaidi Hamad Alharbi, Barbari Khalid Hussine, Omar Mohammed salamah Alburaq, ABDULRAHMAN MOHAMMED HABIB ALHAZMI, Ali Mohammed Alshaikhi, May Motea Sahyoun, Mohammed Mordi Algarni, Fahad Otaibi Alzahrani, Mostafa Mobaireek Alsolami

Abstract :

The issue of antimicrobial medication resistance is a significant global concern. Drug discovery plays a crucial role in addressing present treatment gaps and enhancing established therapeutic methods. However, due to the extensive research duration and substantial expenses involved in introducing novel drugs to the market, focusing on the development of new drugs that target drug-resistant microbes with harmful effects may not be the most optimal approach. The literature was systematically evaluated using databases to identify all relevant research published until the beginning of 2022. In order to uncover novel classes of antibiotics, there is a pressing need for the development of innovative methodologies in rational design and screening-based approaches. The advancement of efficient molecular methodologies for the identification of resistance genes, as well as the exploration of diagnostic biomarkers such as procalcitonin for the purpose of guiding the discontinuation of antibiotic treatment, holds significant value in the effort to mitigate antibiotic usage.

Cite This Article:

Please cite this article in press Ahmed Othman Almailabi et al, An Overview Pharmacist’s Role In Preventing Measures Toward Antibiotic Resistance., Indo Am. J. P. Sci, 2022; 09(3)

Number of Downloads : 10

References:

1. Smith A, Mikanatha NM, Read AF.. Antibiotic resistance: a primer and call to action. Health Commun. 2015;30:1–27.
2. Caron WP, Mousa SA. Prevention strategies for antimicrobial resistance: a systematic review of the literature. Infect Drug Resist. 2010;3:25–33.
3. Ricciardi W, Giubbini G, Laurenti P. Surveillance and control of antibiotic resistance in the Mediterranean region. Mediterr J Hematol Infect Dis. 2016;8:2016036.
4. Asokan GV, Asokan V. Bradford Hill’s criteria, emerging zoonoses, and one health. J Epidemiol Glob Health. 2016;6:125–129.
5. Van Puyvelde S, Deborggraeve S, Jacobs J. Why the antibiotic resistance crisis requires a one health approach. Lancet Infect Dis. 2018;18:132–133.
6. Bassetti M, Poulakou G, Ruppe E, et al. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017;43:1464–1475.
7. World Bank Drug-resistant infections: a threat to our economic future. Washington, DC: World Bank. License: Creative Commons Attribution CC BY 3.0 IGO, 2017.
8. Leal J, Conly J, Henderson EA, et al. How externalities impact an evaluation of strategies to prevent antimicrobial resistance in health care organizations. Antimicrob Resist Infect Control. 2017;6:53.
9. Daulaire N, Bang A, Tomson G, et al. Universal access to effective antibiotics is essential for tackling antibiotic resistance. J Med Law Ethics. 2015;43:17–21.
10. Rather IA, Byung-Chun K, Bajpai VK, et al. Self-medication and antibiotic resistance: crisis, current challenges, and prevention. Saudi J Biol Sci. 2017;24.
11. Vergison A, Dagan R, Arguedas A, et al. Otitis media and its consequences: beyond the earache. Lancet Infect Dis. 2010;10:195–203.
12. Levy C, Pereira M, Guedj R, et al. Impact of 2011 French guidelines on antibiotic prescription for acute otitis media in infants. Me´decine Et Maladies Infectieuses. 2014;44:102–106.
13. Daw MA, Drah AM. Antibiotic resistance: prospects for the new millennium. J Chemother. 2001;13:587–594.
14. Gaygısız Ü, Lajunen T, Gaygısız E. Socio-economic factors, cultural values, national personality and antibiotics use: a cross-cultural study among European countries. J Infect Public Health. 2017;10:755–760. [
15. Rönnerstrand B, Lapuente V. Corruption and use of antibiotics in regions of Europe. Health Policy. 2017;121:250–256.
16. Collignon P, Beggs JJ, Walsh TR, et al. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. Lancet Planet Health. 2018;2:398–405.
17. Peng D, Wang X, Xu Y, et al. Antibiotic misuse among university students in developed and less developed regions of China: a cross-sectional survey. Glob Health Action. 2018;11:1496973.
18. Masterton R. The importance and future of antimicrobial surveillance studies. Clinl Infect Dis. 2008;47:S21–31.
19. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014 Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015.
20. Cassini A, Diaz Högberg L, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19:56–66.
21. Tacconelli E, Pezzani MD. Public health burden of antimicrobial resistance in Europe. Lancet Infect Dis. 2019;19:4–5.
22. de Kraker ME, Stewardson AJ, Harbarth J. Will 10 Million people die a year due to Antimicrobial Resistance by 2050?PLoS Med. 2016;13:1002184.
23. World health Organization Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2016-2017. Geneva: World Health Organization; 2017.
24. World health Organization Antibiotic resistance: multi-country public awareness survey. Geneva: World Health Organization; 2015.
25. Tacconelli E, Peschel A, Autenrieth IB. Translational research strategy: an essential approach to fight the spread of antimicrobial resistance. J Antimicrob Chemother. 2014;69:2889–2891.
26. Hoffman A. Pharmacodynamic aspects of sustained release preparations. Adv Drug Deliv Rev. 1998;33(3):185–199.
27. Hoffman A, Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst. 1999;16(6):571–639.
28. Cao X, Gibbs ST, Fang L, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res. 2006;23(8):1675–1686.
29. Johnson CK, Polk RE, Edmond M, et al. Trends in antimicrobial use from 1999 to 2001 in 36 US hospitals: a SCOPE-MMIT report. Program and abstracts of the 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sept 27–30; San Diego, CA, USA. Abstract K-1005.
30. Stamey TA, Bragonje J. Resistance to nalidixic acid. A misconception due to underdosage. JAMA. 1976;236(16):1857–1860.
31. Dong Y, Zhao X, Domagala J, et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother. 1999;43(7):1756–1758.
32. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001;33(Suppl 3):S147–S156.
33. Madaras-Kelly KJ, Remington RE, Lewis PG, et al. Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol. 2006;27(2):155–169.
34. McDonnell Norms Group Antibiotic overuse: the influence of social norms. J Am Coll Surg. 2008;207(2):265–275.
35. Steinman MA, Gonzales R, Linder JA, et al. Changing use of antibiotics in community-based outpatient practice, 1991–1999. Ann Intern Med. 2003;138(7):525–533.
36. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992–2000. Emerg Infect Dis. 2003;9(4):432–437.
37. Roumie CL, Halasa NB, Grijalva CG, et al. Trends in antibiotic prescribing for adults in the United States – 1995 to 2002. J Gen Intern Med. 2005;20(8):697–702.
38. Molstad S, Erntell M, Hanberger H, et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis. 2008;8(2):125–132.
39. Gross PA, Patel B. Reducing antibiotic overuse: a call for a national performance measure for not treating asymptomatic bacteriuria. Clin Infect Dis. 2007;45(10):1335–1337.
40. Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40(5):643–654.